

TRIPLE-MRD-SCAN: Development and clinical evaluation of a comprehensive multi-dimensional liquid biopsy test for the detection of Molecular Residual Disease in triple negative breast cancer

Principal Investigator (Name/Surname): Prof. Evi Lianidou

1.4. References

1: Gerratana L, et al. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. *Curr Treat Options Oncol.* 2019;20(8):68. Published 2019 Jun 29. doi:10.1007/s11864-019-0667-9

2: Marra A, et al. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. *Cancer J.* 2021 Jan-Feb 01;27(1):41-49. doi: 10.1097/PPO.0000000000000498. PMID: 33475292.

3: Cortes J, et al.; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N Engl J Med.* 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. PMID: 35857659.

4: Fiste O, et al. Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. *Ann Transl Med.* 2020 Dec;8(23):1603. doi: 10.21037/atm-20-1175. PMID: 33437802; PMCID: PMC7791253.

5: Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. *Nat Rev Clin Oncol.* 2021 May;18(5):297-312. doi: 10.1038/s41571-020-00457-x. Epub 2021 Jan 20. PMID: 33473219.

6: Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. *Cancer Discov.* 2021 Apr;11(4):858-873. doi: 10.1158/2159-8290.CD-20-1311. PMID: 33811121).

7: Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. *Semin Cancer Biol.* 2022 Sep;84:69-79. doi: 10.1016/j.semcancer.2022.03.013. Epub 2022 Mar 21. PMID: 35331850

8: Strati A, Markou A, Kyriakopoulou E, Lianidou E. Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting. *Cancers (Basel).* 2023 Apr 6;15(7):2185. doi: 10.3390/cancers15072185. PMID: 37046848; PMCID: PMC10092977.

9. Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. *Nat Rev Cancer.* 2023 Feb;23(2):95-111. doi: 10.1038/s41568-022-00536-4. Epub 2022 Dec 9. PMID: 36494603; PMCID: PMC9734934.

10: Cristofanilli M, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Vol. 134, *Critical Reviews in Oncology/Hematology.* Elsevier Ireland Ltd; 2019. p. 39–45

11: Stathopoulou A, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. *Journal of Clinical Oncology.* 2002 Aug 15;20(16):3404–12)

- 12: Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, Georgoulas V, Lianidou ES. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. *Clin Cancer Res.* 2003 Nov 1;9(14):5145-51. PMID: 14613993.
- 13: Strati A, et al. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. *Clin Chem.* 2021 Oct 1;67(10):1395-1405. doi: 10.1093/clinchem/hvab099. PMID: 34322698.)
- 14: Heitzer E, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet.* 2019 Feb;20(2):71-88. doi: 10.1038/s41576-018-0071-5. PMID: 30410101
- 15: Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. *Nat Rev Cancer.* 2023 Feb;23(2):95-111. doi: 10.1038/s41568-022-00536-4. Epub 2022 Dec 9. PMID: 36494603; PMCID: PMC9734934.
- 16: Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, Kallergi G, Georgoulas V, Lianidou E. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. *Sci Rep.* 2023 Jan 23;13(1):1258. doi: 10.1038/s41598-022-25400-1. PMID: 36690653; PMCID: PMC9870904.
- 17: Rossi G, et al. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. *Clin Cancer Res.* 2018;24(3):560-568. doi:10.1158/1078-0432.CCR-17-2092)
- 18: Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059. PMID: 35022204.).
- 19: Esteller M. Molecular origins of cancer: Epigenetics in cancer. Vol. 358, *New England Journal of Medicine.* N Engl J Med; 2008.
- 20: Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Vol. 3, *Nature Reviews Genetics.* Nat Rev Genet; 2002. p. 415–28.
- 21: Kanwal R, et al. Cancer epigenetics: an introduction. Vol. 1238, *Methods in molecular biology (Clifton, N.J.).* Methods Mol Biol; 2015. p. 3–25.
- 22: Lianidou E. Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook. *Mol Oncol.* 2021 Jun;15(6):1683-1700. doi: 10.1002/1878-0261.12978. Epub 2021 May 14. PMID: 33942482; PMCID: PMC8169441
- 23: Chimonidou M, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. *Clinical Chemistry.* 2011 Aug;57(8):1169–77.),
- 24: Pixberg CF, et al. Characterization of DNA methylation in circulating tumor cells. Vol. 6, *Genes.* MDPI AG; 2015. p. 1053–75.),
- 25: Gkoutela S, et al. Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. *Cell.* 2019 Jan 10;176(1-2):98-112.e14. doi: 10.1016/j.cell.2018.11.046. PMID: 30633912; PMCID: PMC6363966.).

- 26: Chimonidou M, et al. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. *Clinical chemistry*. 2013 Jan 1;59(1):270–9.).
- 27: Mastoraki S, et al. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. *Clin Cancer Res*. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28. PMID: 29284708.).
- 28: Takahashi H, et al.. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. *Clin Breast Cancer*. 2017 Feb;17(1):61-69.e3. doi: 10.1016/j.clbc.2016.06.006. Epub 2016 Jun 16. PMID: 27395416.).
- 29: Zavridou M, et al.Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. *Clin Chem*. 2018 Oct;64(10):1522-1533. doi: 10.1373/clinchem.2018.292318. Epub 2018 Jul 17. PMID: 30018056.).
- 30: Ntzifa A, Lianidou E. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. *Crit Rev Clin Lab Sci*. 2023 Dec;60(8):573-594. doi: 10.1080/10408363.2023.2230290. Epub 2023 Jul 30. PMID: 37518938.
- 31: Connors D, et al.. International liquid biopsy standardization alliance white paper. *Crit Rev Oncol Hematol*. 2020 Dec;156:103112. doi: 10.1016/j.critrevonc.2020.103112. Epub 2020 Sep 30. PMID: 33035734
- 32: Henry NL, et al. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. 2022 Sep 20;40(27):3205-3221. doi: 10.1200/JCO.22.01063. Epub 2022 Jun 27. PMID: 35759724.
- 33: Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. *Nat Rev Clin Oncol*. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3. PMID: 30796368.
- 34: Peng Y, et al. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. *Front Oncol*. 2021 Nov 18;11:763790. doi: 10.3389/fonc.2021.763790. PMID: 34868984; PMCID: PMC8637327.
- 35: Wan JCM et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. *Sci Transl Med*. 2020 Jun 17;12(548):eaaz8084. doi: 10.1126/scitranslmed.aaz8084. PMID: 32554709.
- 36: Lipsyc-Sharf M, et al.. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. *J Clin Oncol*. 2022 Aug 1;40(22):2408-2419. doi: 10.1200/JCO.22.00908. Epub 2022 Jun 4. PMID: 35658506; PMCID: PMC9467679.
- 37: Zhou Q, et al. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. *Clin Cancer Res*. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231. PMID: 34862246.

- 38: Parsons HA, et al. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. *Clin Cancer Res*. 2020 Jun 1;26(11):2556-2564. doi: 10.1158/1078-0432.CCR-19-3005. Epub 2020 Mar 13. PMID: 32170028; PMCID: PMC7654718.
- 39: Papakonstantinou A, et al. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. *Cancer Treat Rev*. 2022 Mar;104:102362. doi: 10.1016/j.ctrv.2022.102362. Epub 2022 Feb 18. PMID: 35219090.)
- 40: Magbanua MJM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. *Ann Oncol*. 2021 Feb;32(2):229-239. doi: 10.1016/j.annonc.2020.11.007. Epub 2020 Nov 21. PMID: 33232761; PMCID: PMC9348585.
- 41: Cailleux F, Agostinetti E, Lambertini M, Rothé F, Wu HT, Balcioglu M, Kalashnikova E, Vincent D, Viglietti G, Gombos A, Papagiannis A, Veys I, Awada A, Sethi H, Aleshin A, Larsimont D, Sotiriou C, Venet D, Ignatiadis M. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. *JCO Precis Oncol*. 2022 Sep;6:e2200148. doi: 10.1200/PO.22.00148. PMID: 36170624.
- 42: McDonald BR, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. *Sci Transl Med*. 2019 Aug 7;11(504):eaax7392. doi: 10.1126/scitranslmed.aax7392. PMID: 31391323; PMCID: PMC7236617.
- 43: Bidard FC, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, Goncalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero JM, Loirat D, Cabel L, Kadi A, Diéras V, Alix-Panabières C, Pierga JY. Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. *J Clin Oncol*. 2023 Nov 6;JCO2300456. doi: 10.1200/JCO.23.00456. Epub ahead of print. PMID: 37931185.
- 44: Bidard FC, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. *J Natl Cancer Inst*. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018. PMID: 29659933.
- 45: Cescon DW et al. Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. *Front Oncol*. 2022 Feb 10;11:667397. doi: 10.3389/fonc.2021.667397. PMID: 35223447; PMCID: PMC8867255.
- 46: Salvador-Coloma C, et al. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. *Eur J Cancer*. 2020 Nov;139:119-134. doi: 10.1016/j.ejca.2020.08.020. Epub 2020 Sep 29. PMID: 32987253.
- 47: Valencia GA et al. PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report. *World J Clin Oncol*. 2021 Aug 24;12(8):702-711. doi: 10.5306/wjco.v12.i8.702. PMID: 34513603; PMCID: PMC8394163.
- 48: Riva F, et al. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Clin Chem*. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10. PMID: 28073896.

49: Ortolan E, et al. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. *ESMO Open*. 2021 Apr;6(2):100086. doi: 10.1016/j.esmoop.2021.100086. Epub 2021 Mar 17. PMID: 33743331; PMCID: PMC8010400).

50: Schneider BP, et al. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. *J Clin Oncol*. 2022 Feb 1;40(4):345-355. doi: 10.1200/JCO.21.01657. Epub 2021 Dec 15. PMID: 34910554.

51: Radovich M, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. *JAMA Oncol*. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. PMID: 32644110; PMCID: PMC7349081.

52: Okines A, Turner N. Developing therapies for triple-negative breast cancer subtypes. *Lancet Oncol*. 2024 Jan 8:S1470-2045(23)00639-3. doi: 10.1016/S1470-2045(23)00639-3. Epub ahead of print. PMID: 38211607.

Amato O, Aftimos P, Ignatiadis M. Liquid biopsy accelerates precision medicine. *Ann Oncol*. 2023 Apr;34(4):333-335. doi: 10.1016/j.annonc.2023.02.004. Epub 2023 Feb 16. PMID: 36804455.

53: Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. *Ann Oncol*. 2023 Oct;34(10):899-906. doi: 10.1016/j.annonc.2023.08.004. Epub 2023 Aug 18. PMID: 37597579.

54: Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley AM, Wheatley D, Waters S, Winter MC, Hubank M, Allen SD, Bliss JM; c-TRAK TN investigators. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. *Ann Oncol*. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22. PMID: 36423745.

55: Go J, Ahn JH, Park JM, Choi SB, Kim JY, Park HS, Kim SI, Park BW, Park S. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy. *Ann Surg Oncol*. 2023 Nov;30(12):7060-7068. doi: 10.1245/s10434-023-13938-x. Epub 2023 Aug 3. PMID: 37537485.

56: Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized

phase II study. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. PMID: 38105958; PMCID: PMC10723519.

57: Sun Y, Zhu C, Xu F, Cui S, Guan X. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer. *Clin Breast Cancer*. 2023 Jun;23(4):339-349. doi: 10.1016/j.clbc.2023.02.012. Epub 2023 Mar 2. PMID: 36966079.

58: Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. *Curr Treat Options Oncol*. 2021 Jul 2;22(9):79. doi: 10.1007/s11864-021-00879-4. PMID: 34213636.

59: Singh A, Georgy JT, Dhananjayan S, Sigamani E, John AO, Joel A, Chandramohan J, Abarna R, Rebekah G, Backianathan S, Abraham DT, Paul MJ, Chacko RT, Manipadam MT, Pai R. Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease. *Gene*. 2024 Feb 15;895:147980. doi: 10.1016/j.gene.2023.147980. Epub 2023 Nov 10. PMID: 37951371.

60: Mai N, Abuhadra N, Jhaveri K. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions. *Clin Breast Cancer*. 2023 Dec;23(8):784-799. doi: 10.1016/j.clbc.2023.05.012. Epub 2023 May 28. PMID: 37336650.

61: Shen SY, Burgener JM, Bratman SV, De Carvalho DD. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. *Nat Protoc*. 2019 Oct;14(10):2749-2780. doi: 10.1038/s41596-019-0202-2. Epub 2019 Aug 30. PMID: 31471598.

62: Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N, Georgoulas V, Lianidou ES. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer*. 2006 Oct 1;119(7):1654-9. doi: 10.1002/ijc.22017. PMID: 16708381.

63: Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Ann Oncol*. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206. PMID: 28838214.